Intriguing issues of EGFR targeting in head and neck cancer [4]

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 962-

  Karamouzis, M V ^a,b   Konstantinopoulos, P A ^a,c   Papavassiliou, A G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LIGAND; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CELL; CANCER RADIOTHERAPY; DRUG HALF LIFE; DRUG TARGETING; ENDOCYTOSIS; ENDOSOME; HEAD AND NECK CANCER; INTERNALIZATION; IONIZING RADIATION; LETTER; LYSOSOME; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34447302322     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm117     Document Type: Letter

References (10)

1. Cruz JJ, Ocana A, Del Barco E, Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes n head and neck cancer. Ann Oncol 2007; 18 421-430.
2. Frey MR, Dise RS, Edelblum KL, Polk DB. p38 regulates epidermal growth factor receptor downregulation and cellular migration. EMBO J 2006; 25: 5683-5692.
3. Citri A, Yarden Y. EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-516.
4. Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12: 5064-5073.
5. Thomas SM, Bhola NE, Zhang Q et al. Cross-talk between G protein-coupled receptors and epidermal growth factor receptor signalling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006; 66: 11831-11839.
6. Ingram JL, Bonner JC. EGF and PDGF receptor tyrosine kinasea as therapeutic targets for chronic lung diseases. Curr Mol Med 2006; 6: 409-421.
7. Karamouzis MV, Papavassilou AG. The IGF-1 network in lung carcinoma therapeutics. Trends Mol Med 2006; 12: 595-602.
8. Gururaj AE, Rayala SK, Vadlamudi RK, Kumar R Novel mechanisms of resistance to endocrine therapy: Genomic and nongenomic considerations. Clin Cancer Res 2006; 12 (3 Pt 2): 1001s-1007s
9. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006; 6: 876-885.
10. Feng FY, Varambally S, Tomlins SA et al. Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 2006. doi:10.1038/spj.onc.1210129.